Enzalutamide-resistant related lncRNA NONHSAT210528 promotes the proliferation and invasion of prostate cancer

BACKGROUND: As a new-generation androgen-receptor antagonist, enzalutamide is a first-choice drug for advanced prostate cancer (PCa) patients. However, secondary resistance to enzalutamide poses a new challenge in the treatment of cancer. Long non-coding RNA (lncRNA) regulates cell function through...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Chen, Chen, Yuan-Gui, Qin, Sheng-Fei, Tang, Shou-Yan, Li, Song, Shi, Min-Feng, Zhou, Tie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177268/
https://www.ncbi.nlm.nih.gov/pubmed/35693714
http://dx.doi.org/10.21037/tau-22-99

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177268/
https://www.ncbi.nlm.nih.gov/pubmed/35693714
http://dx.doi.org/10.21037/tau-22-99

Ejemplares similares